地塞米松治疗已发生的术后恶心呕吐:随机剂量探索试验
这项多中心、安慰剂对照、随机双盲剂量探索试验纳入281例全麻术后已发生PONV的成人,随机给予地塞米松3、6或12 mg或安慰剂。结果显示地塞米松在给药后24小时内对已发生的PONV无效,各剂量与安慰剂相比均无差异(P=0.170),且未观察到剂量反应关系;地塞米松剂量与血糖浓度呈正相关(P<0.001),但与出血风险、伤口感染或其他不良反应无关。
要点
- 地塞米松3、6、12 mg静脉给药均不能有效治疗已发生的PONV。
- 地塞米松剂量与血糖升高呈正相关,但未增加出血或感染风险。
- 地塞米松用于预防PONV的既有证据不应外推至已发生的PONV治疗。
核心结论
- 本随机试验未能显示任何测试剂量的静脉地塞米松对全麻术后成人已发生的PONV具有止吐疗效。
研究设计与样本
- DexPonv试验为多中心、安慰剂对照、随机、双盲、剂量探索研究,在瑞士4家公立医院进行。
- 803例拟行择期手术且未接受止吐预防的成人签署知情同意,714例纳入,其中319例发生PONV,最终281例随机分组(意向治疗集和安全集),符合方案集260例。
- 患者随机接受单次静脉地塞米松3、6或12 mg或匹配安慰剂。
- 主要终点为给药后24小时内无进一步恶心或呕吐(包括干呕)。
主要发现
- 地塞米松在给药后24小时内无效,无论剂量如何,与安慰剂相比均无差异,即使模型校正已知危险因素后仍无差异(P=0.170)。
- 治疗失败时间和第一夜睡眠质量无差异。
- 地塞米松剂量与血糖浓度呈正相关(P<0.001),但与出血风险、伤口感染或其他不良反应无关。
临床怎么用
- 对于全麻术后已发生的PONV,不应期望使用地塞米松3、6或12 mg静脉给药能有效止吐。
- 使用地塞米松时应关注血糖升高,尤其在高剂量时。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dexamethasone is widely used for the prevention of postoperative nausea and vomiting (PONV) but little is known about its efficacy for the treatment of established PONV. OBJECTIVE: To test the antiemetic efficacy of intravenous dexamethasone for the treatment of established PONV in adults undergoing surgery under general anaesthesia and to determine whether there is dose-responsiveness. DESIGN: The DexPonv trial is a multicentre, placebo-controlled, randomised, double-blind, dose-finding study. Inclusion of patients was between September 2012 and November 2017. Follow-up for PONV symptoms was for 24 h. Thirty days postoperatively, patients were contacted by study nurses for any information on postoperative bleeding and infection. SETTING: Four public hospitals in Switzerland. PATIENTS: A total of 803 adults scheduled for elective surgery without any antiemetic prophylaxis signed the consent form; 714 were included. Among those, 319 had PONV and 281 patients were eventually randomised (intention to treat population and safety set). The per protocol set consisted of 260 patients. INTERVENTIONS: Patients with PONV symptoms (including retching) were randomised to a single intravenous dose of dexamethasone 3, 6 or 12 mg or matching placebo. MAIN OUTCOME MEASURES: The primary endpoint was the absence of further nausea or vomiting (including retching), within 24 h after administration of the study drug. RESULTS: Dexamethasone was ineffective during the first 24 h, whatever the dosage, compared to placebo, even when the model was adjusted for known risk factors (P = 0.170). There were no differences in the time to treatment failure or the quality of sleep during the first night. There was a positive correlation between the dose of dexamethasone and blood glucose concentrations (P < 0.001), but not with bleeding risk, wound infections or other adverse effects. CONCLUSION: This randomised trial failed to show anti-emetic efficacy of any of the tested intravenous regimens of dexamethasone for the treatment of established PONV in adults undergoing surgery under general anaesthesia. TRIAL REGISTRATION: clinicaltrials.gov (NCT01975727).
引用
- Czarnetzki C, Albrecht E, Desmeules J, et al. Dexamethasone for the treatment of established postoperative nausea and vomiting: A randomised dose finding trial. Eur J Anaesthesiol. 2021. PMID: 34799501. doi:10.1097/EJA.0000000000001636
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。